This phase III trial is trying to determine whether the combination of an immunotherapy (Durvalumab) and a standard of care therapy (Bacillus Calmette-Guerin) is better than giving standard of care therapy alone, in the treatment of non-muscle-invasive bladder cancer.
This trial is treating patients with bladder cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients
Eligible patients will be randomised in a 1:1:1 to receive Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy (as induction and/or maintenance therapy) or Bacillus Calmette-Guerrin (BCG) alone.
Recruiting Hospitals Read More